Pharma Mar, S.A. (BME:PHM)

Revenue by Segment

Financials in millions EUR. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
Oncology	221.35M	174.59M	156.84M	191.18M	224.67M
Oncology Growth	26.78%	11.32%	-17.96%	-14.91%	-12.49%
RNA Interference (RNAi)	36.00K	262.00K	121.00K	31.00K	3.00K
RNA Interference (RNAi) Growth	-86.26%	116.53%	290.32%	933.33%	-25.00%
Unallocated Parent company expenses	-	-	1.19M	-	-
Others	-	-	-	5.13M	5.16M
Others Growth	-	-	-	-0.52%	-60.81%
Total	221.39M	174.86M	158.15M	196.34M	229.83M
Total Growth	26.61%	10.56%	-19.45%	-14.57%	-14.87%

Revenue by Geography

Financials in millions EUR. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
Spain	2.48M	3.90M	6.93M	16.64M	17.35M
Spain Growth	-36.41%	-43.68%	-58.36%	-4.08%	-27.56%
Ireland	100.62M	78.94M	75.36M	86.79M	110.00M
Ireland Growth	27.47%	4.75%	-13.17%	-21.10%	-28.46%
Germany	27.13M	4.88M	4.64M	14.98M	18.21M
Germany Growth	456.00%	5.22%	-69.05%	-17.74%	-1.57%
France	24.24M	22.13M	30.00M	17.39M	-
France Growth	9.51%	-26.24%	72.54%	-	-
United States	20.13M	22.41M	12.51M	13.37M	2.31M
United States Growth	-10.19%	79.14%	-6.40%	477.57%	3.12%
Switzerland	6.42M	-	-	-	-
Rest of EU	12.26M	12.06M	10.90M	18.92M	53.32M
Rest of EU Growth	1.65%	10.64%	-42.40%	-64.52%	22.48%
Others	28.12M	24.82M	13.63M	13.09M	11.48M
Others Growth	13.28%	82.11%	4.17%	14.00%	11.72%
China	-	5.72M	-	-	-
Italy	-	-	4.19M	15.17M	17.15M
Italy Growth	-	-	-72.40%	-11.53%	-3.09%
Total	221.39M	174.86M	158.15M	196.34M	229.83M
Total Growth	26.61%	10.56%	-19.45%	-14.57%	-14.87%

Source: S&P Global Market Intelligence.